2025-521407-52-00招募中1 期
A Phase 1 Study of JNJ-89862175, an Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 Antibody Drug Conjugate, for Advanced Solid Tumors.
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 120
- 试验地点
- 2
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
CTIS Point of Contact
Scientific
Janssen Cilag International
研究点 (2)
Loading locations...
相似试验
招募中
1 期
A Phase 1 Study of JNJ-87189401 Combined with JNJ-78278343 for Advanced Prostate Cancer2023-504063-17-00Janssen - Cilag International48
招募中
3 期
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT07258511Janssen Research & Development, LLC400
招募中
1 期
A Phase 1 Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors2023-504896-26-00Janssen - Cilag International80
招募中
1 期
A First-in-Human Dose Escalation Study of JNJ-79635322, in Participants with Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis2023-503679-12-00Janssen - Cilag International75
已完成
不适用
Observation Study of Patients With Non-Small Cell Lung Cancer and Carcinomatous Meningitis Treated With whole-brain radiation or/and immune checkpoint inhibitors.on-small cell lung cancerJPRN-UMIN000040704orth East Japan Study Group (NEJSG)300